

SPARC/Sec/SE/2025-26/49

January 11, 2026

National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.

BSE Limited,
Market Operations Dept.
P. J. Towers,
Dalal Street,
Mumbai - 400 001.

Scrip Symbol: SPARC

Scrip Code: 532872

Dear Sir/ Madam,

Sub: Prior Intimation under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“SEBI Listing Regulations”).

Dear Sir/Madam,

With reference to the captioned subject, this prior intimation is being given to intimate that the meeting of the board of directors of Sun Pharma Advanced Research Company Limited (“Company”) is scheduled to be held on Wednesday, January 14, 2026 to inter alia consider below agenda items:

1. To consider, evaluate and, if thought fit, to approve the proposal for raising funds by the Company through a preferential issue of securities, including convertible warrants, to an identified member of the promoter group of the Company, in accordance with the provisions of Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, the Companies Act, 2013 and the rules made thereunder, and other applicable laws, as amended subject to receipt of all requisite approvals, consents and permissions, including the approval of the members of the Company and National Stock Exchange of India Limited (“NSE”) and BSE Limited (“BSE”); and
2. To consider, evaluate and, if thought fit, to approve the Employee Stock Option Scheme in terms of Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, as amended read with the Companies Act, 2013 and the rules made thereunder, and other applicable laws, as amended subject to receipt of all requisite approvals, consents and permissions, including the approval of the members of the Company and NSE and BSE.

Further, pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended, and the Company’s code of conduct for prohibition of insider trading, the Trading Window for dealing in shares of the Company has been closed effective from January 01, 2026 and shall remain closed as communicated vide our letter dated December 29, 2025.

This is for your information and record.

For **Sun Pharma Advanced Research Company Ltd.**

Kajal Damania
Company Secretary and Compliance Officer